The relationship between serum tumor-associated trypsin inhibitor levels and clinicopathological parameters in patients with gastric cancer

Kemik, O.; Kemik, A.; Sumer, A.; Almalı, Necat; Gurluler, ERCÜMENT; Gures, N.; Purisa, S.; Adas, G.; Dogan, Y.; Tuzun, S.

The relationship between serum tumor-associated trypsin inhibitor levels and clinicopathological parameters in patients with gastric cancer

Atıf İçin Kopyala

Kemik O., Kemik A., Sumer A., Almalı N., Gurluler E., Gures N., ...Daha Fazla

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, cilt.17, sa.21, ss.2923-2928, 2013 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 17 Sayı: 21
Basım Tarihi: 2013
Dergi Adı: EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.2923-2928
Anahtar Kelimeler: Tumor-associated trypsin inhibitor, Clinical-pathological features, Gastric cancer, COLON-CANCER, EXPRESSION, TATI, FIBROBLASTS, ANTIGEN, URINE
Bursa Uludağ Üniversitesi Adresli: Hayır

Özet

BACKGROUND: Tumor-associated trypsin inhibitor (TATI) is expressed with trypsinogen in tumors. We studied the clinical-pathologic association and significance of preoperative serum levels of TATI in gastric cancer patients.